Ventricular assist devices are external devices attached to a patient’s body, which helps to pump blood to whole body. It is principally used in case of patients with heart failure. It is a high-end device that mimics the function of the heart. Heart failure is a condition in which heart muscles weaken, and thus unable to pump sufficient amount of blood to body. Various conditions such as heart attacks, high blood pressure, defective heart valves, irregular heart rhythms, diabetes, and chronic kidney and lung diseases cause heart failure. Medication, implantable heart devices (pacemakers), and heart transplantation are some of the options for treatment of heart failure. However, these approaches have limitations that may lead to advanced heart failure condition, thereby increasing the demand for ventricular assist devices (VADs). VADs lowers the work load on failing heart and help in maintaining smooth blood flow to vital organs. These devices were originally designed to temporarily assist surgeons while performing transplant surgeries or while treating other medical problems. However, VADs eventually emerged as a pioneer life support for patients suffering from the final stage of heart failure. VADs consist of three parts namely, inflow pipe that receives blood from ventricles, pump that pulls blood from ventricles and pushes it into outflow pipe that carries blood to aorta to supply blood to body
Growth of ventricular assist devices market is driven by increasing prevalence of heart failure. According to study the Global Burden of Disease published by the Lancet in 2017, globally over 26 million people were affected by heart failure. Moreover, rising prevalence of cardiovascular diseases, which causes heart failure, is increasing the demand for ventricular assist devices. According to World Health Organization factsheet in 2016, 17.7 million people die from cardiovascular disease each year, and over 46% of these deaths are due to ischemic heart disease that includes heart failure. Other disease such as diabetes is triggering to development of heart failure, which in turn, is propelling growth of the ventricular assist devices market. As per statistics provided by the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million patients were suffering from diabetes worldwide in 2017. According to statistics given by the American Heart Association in 2018, 68% of people suffering from diabetes aged 65 years and above are likely to die from heart disease. Sedentary lifestyle, lack of exercise, unhealthy food habits, and alcoholism are major cause to develop the heart disease. Growing shortage of heart donors for transplantation is also expected to boost growth of the ventricular assist devices market. According to report published by the Global Observatory on Donations and Transplantation in 2015, only around 0.01-0.49 per million heart transplantation procedures are performed each year in emerging countries due to shortage of donors. Continuous improvement in design, efficiency, and reliability is also propelling growth of the ventricular assist devices market. For instance, in April 2018, Abiomed Inc. was granted with U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its Impella CP heart pump with smart assist technology, which utilizes an optical sensor. It is an advanced device that would improve productivity, ease in use, and better patient management.
However, these devices being highly specialized, are high in cost, which in turn, hinders growth of the market for VADs. Additionally, continuous improvement in other treatment option for heart failure condition such as advanced pacemakers would limit the market growth for ventricular assist devices.
Ventricular assist devices market is geographically divided into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The market in North America is expected to hold a dominant position in the VADs market during forecasted period due to high prevalence of heart failure and affordability of these devices in the region. According to a study published in the Journal Circulation in 2016, over 5.7 million people in the U.S. suffered suffering from HF (heart failure), which is expected to increase to 8 million by 2030 and over 250,000 patients are expected to develop advanced heart failure, thus requiring VADs. Shortage of heart donors in the U.S. is also expected to drive growth of the market. According to statistics provided by the American College of Cardiology in 2017, only 2,200 heart donor are available each year in the U.S. Europe is a lucrative region for ventricular assist devices market, as it accounts for the highest geriatric population in world according UN report in 2017 (25% of entire population) along with high prevalence of heart failure. According to report by the European Heart Network, in 2017, cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union, each year. Asia Pacific is expected to represent enormous opportunities for market growth in the near future, owing to the growing mortality rate caused due to CVD in the region. More than 75% deaths occurs in middle-low income countries 2as per WHO factsheet 2016)
Key players operating in the ventricular assist devices market include Abiomed, Inc., Abbott Laboratories, Heart Ware International, Inc, Berlin Heart GmbH, Thoratec, Inc., Liva Nova plc, Jarvik Heart, Inc., Medtronic plc, ReliantHeart, Inc., and Calon Cardio-Technology Ltd
On the basis of application, ventricular assist devices market is segmented into
On the basis of product type, ventricular assist devices market is segmented into
On the basis of design, ventricular assist devices market is segmented into
On the basis of region, ventricular assist devices market is segmented into